Morris, Z. S., Demaria, S., Monjazeb, A. M., Formenti, S. C., Weichselbaum, R. R., Welsh, J., Enderling, H., Schoenfeld, J. D., Brody, J. D., McGee, H. M., Mondini, M., Kent, M. S., Young, K. H., Galluzzi, L., Karam, S. D., Theelen, W. S. M. E., Chang, J. Y., Huynh, M. A., Daib, A., … Fong, L. (2025). Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. The Lancet Oncology, 26(3), e152–e170. https://doi.org/10.1016/s1470-2045(24)00656-9

Yoon, A. J., Carvajal, R. D., Graboyes, E. M., Kaczmar, J. M., Albergotti, W. G., Kejner, A. E., Troob, S. H., Philipone, E., Anoma, J.-S., Armeson, K. E., Hill, E. G., Richardson, M. S., Woods, T. R., Chera, B. S., Nourollah-Zadeh, F., Lee, B. J., Pandruvada, S., Kourtidis, A., Kingsley, C., … Newman, J. G. (2025). Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1530262

Redenti, A., Im, J., Redenti, B., Li, F., Rouanne, M., Sheng, Z., Sun, W., Gurbatri, C. R., Huang, S., Komaranchath, M., Jang, Y., Hahn, J., Ballister, E. R., Vincent, R. L., Vardoshivilli, A., Danino, T., & Arpaia, N. (2024). Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature, 635(8038), 453–461. https://doi.org/10.1038/s41586-024-08033-4

Gao, L., & Ding, L. (2024). METTL3: Melting the tumor microenvironment for improved immunotherapy. Cell Chemical Biology, 31(4), 629–631. https://doi.org/10.1016/j.chembiol.2024.03.005

Goubet, A.-G., Rouanne, M., Derosa, L., Kroemer, G., & Zitvogel, L. (2023). From mucosal infection to successful cancer immunotherapy. Nature Reviews Urology, 20(11), 682–700. https://doi.org/10.1038/s41585-023-00784-5

Miholjcic, T. B. S., Halse, H., Bonvalet, M., Bigorgne, A., Rouanne, M., Dercle, L., Shankar, V., & Marabelle, A. (2023). Rationale for LDH-targeted cancer immunotherapy. European Journal of Cancer, 181, 166–178. https://doi.org/10.1016/j.ejca.2022.11.032

Obradovic, A. (2023). Precision immunotherapy. Science, 379(6633), 654–655. https://doi.org/10.1126/science.adg5585

Klein, R. M. (2022). Calvin Coolidge’s “rose fever.” Annals of Allergy, Asthma & Immunology, 129(1), 125–126. https://doi.org/10.1016/j.anai.2022.03.034

de Vries, E. G., & Schwartz, L. H. (2022). Perspectives on imaging and immunotherapy: a review series. Journal for ImmunoTherapy of Cancer, 10(6), e005006. https://doi.org/10.1136/jitc-2022-005006

Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., … Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), e003776. https://doi.org/10.1136/jitc-2021-003776